NovaBay Pharmaceuticals Statistics Share Statistics NovaBay Pharmaceuticals has 5.82M
shares outstanding. The number of shares has increased by 19.05%
in one year.
Shares Outstanding 5.82M Shares Change (YoY) 19.05% Shares Change (QoQ) 0% Owned by Institutions (%) 0% Shares Floating 5.82M Failed to Deliver (FTD) Shares 4,652 FTD / Avg. Volume 13.02%
Short Selling Information The latest short interest is 38.26K, so 0.66% of the outstanding
shares have been sold short.
Short Interest 38.26K Short % of Shares Out 0.66% Short % of Float 0.74% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.28 and the forward
PE ratio is -1.58.
NovaBay Pharmaceuticals's PEG ratio is
0.
PE Ratio -0.28 Forward PE -1.58 PS Ratio 0.21 Forward PS 0.2 PB Ratio -15.82 P/FCF Ratio -0.39 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for NovaBay Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.68,
with a Debt / Equity ratio of -12.96.
Current Ratio 0.68 Quick Ratio 0.41 Debt / Equity -12.96 Debt / EBITDA -0.28 Debt / FCF -0.32 Interest Coverage -6.46
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $752.38K Profits Per Employee $-555.62K Employee Count 13 Asset Turnover 2.86 Inventory Turnover 4.31
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 44.2% in the
last 52 weeks. The beta is 0.41, so NovaBay Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.41 52-Week Price Change 44.2% 50-Day Moving Average 0.61 200-Day Moving Average 0.62 Relative Strength Index (RSI) 42.93 Average Volume (20 Days) 35,743
Income Statement In the last 12 months, NovaBay Pharmaceuticals had revenue of 9.78M
and earned -7.22M
in profits. Earnings per share was -2.53.
Revenue 9.78M Gross Profit 6.48M Operating Income -5.84M Net Income -7.22M EBITDA -5.92M EBIT -6.31M Earnings Per Share (EPS) -2.53
Full Income Statement Balance Sheet The company has 430K in cash and 1.67M in
debt, giving a net cash position of -1.24M.
Cash & Cash Equivalents 430K Total Debt 1.67M Net Cash -1.24M Retained Earnings -183.46M Total Assets 9.87M Working Capital 5.97M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -5.18M
and capital expenditures -6K, giving a free cash flow of -5.19M.
Operating Cash Flow -5.18M Capital Expenditures -6K Free Cash Flow -5.19M FCF Per Share -1.53
Full Cash Flow Statement Margins Gross margin is 66.26%, with operating and profit margins of -59.7% and -73.85%.
Gross Margin 66.26% Operating Margin -59.7% Pretax Margin -73.71% Profit Margin -73.85% EBITDA Margin -60.58% EBIT Margin -59.7% FCF Margin -53.05%
Dividends & Yields NBY does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for NBY is $0.85,
which is 41.7% higher than the current price. The consensus rating is "Buy".
Price Target $0.85 Price Target Difference 41.7% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 31, 2024. It was a
backward
split with a ratio of 1:35.
Last Split Date May 31, 2024 Split Type backward Split Ratio 1:35
Scores Altman Z-Score -25.18 Piotroski F-Score 4
